Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACACIA
NCT06205602Phase 2Active, not recruiting
- Start
- Jan 2025
- Primary completion
- Feb 2029
- Modality
- Anti-infectious Disease mAbs
- Countries
- 2
01
Overview
A Phase 2 trial of zinlirvimab, Teropavimab in human immunodeficiency virus infection (HIV). Started Jan 2025; status: active, not recruiting.
02
Drugs
zinlirvimabTeropavimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06205602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205602.